Chromatin-Remodeled State in Lymphoma
Purpose of Review
Emerging evidence has shown that epigenetic derangements might drive and promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. The purpose of this review is to explain how the epigenetic derangements result in a chromatin-remodeled state in lymphoma and contribute to the biology and clinical features of these tumors.
Studies have explored on the functional role of epigenetic derangements in chromatin remodeling and lymphomagenesis. For example, the haploinsufficiency of CREBBP facilitates malignant transformation in mice and directly implicates the importance to re-establish the physiologic acetylation level. New findings identified 4 prominent DLBCL subtypes, including EZB-GC-DLBCL subtype that enriched in mutations of CREBBP, EP300, KMT2D, and SWI/SNF complex genes. EZB subtype has a worse prognosis than other GCB-tumors. Moreover, the action of the histone modifiers as well as chromatin-remodeling factors (e.g., SWI/SNF complex) cooperates to influence the chromatin state resulting in transcription repression. Drugs that alter the epigenetic landscape have been approved in T cell lymphoma. In line with this finding, epigenetic lesions in histone modifiers have recently been uncovered in this disease, further confirming the vulnerability to the therapies targeting epigenetic derangements.
Modulating the chromatin state by epigenetic-modifying agents provides precision-medicine opportunities to patients with lymphomas that depend on this biology.
KeywordsChromatin Lymphoma Epigenetics
Compliance with Ethical Standards
Conflict of Interest
Dr. Amengual declares that she has received a grant from Appia Pharmaceuticals and has been paid to speak by Epizyme. Dr. Yuxuan and Dr. Rosario have no conflicts to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.• Morschhauser F, Tilly H, Chaidos A, et al. Interim update from a phase 2 multicenter study of tazemetostat, an Ezh2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Hematol Oncol. 2019;37:154–6 The most recent updated report showed the promising efficacy of EZH2 inhibitor in follicular lymphoma. CrossRefGoogle Scholar
- 9.Maruyama D, Tobinai K, Makita S, et al. First-in-human study of the EZH1/2 dual inhibitor DS-3201b in patients with relapsed or refractory non-Hodgkin lymphomas — preliminary results. Blood. 2017;130:4070.Google Scholar
- 10.Gupta M, Demosthenous C, Stenson MJ, Price-Troska T. Oncogenic role of chromatin modifier polycomb repressive Complex-2 in mantle cell lymphoma. Blood. 2018;132:1582.Google Scholar
- 11.• Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, et al. Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin Cancer Res. 2019. http://clincancerres.aacrjournals.org/content/early/2019/07/10/1078-0432.CCR-18-3989.abstract. This is the first manuscript to demonstrate the synergistic effects by dual targeting EZH2 and HDAC in B cell lymphoma preclinical models.
- 14.Xin C, Wang C, Wang Y, Zhao J, Wang L, Li R, et al. Identification of novel KMT2D mutations in two Chinese children with kabuki syndrome: a case report and systematic literature review. BMC Med Genet. 2018;19:31.Google Scholar
- 31.•• Cerchietti LC, Hatzi K, Caldas-Lopes E, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010;120:4569–82 The first paper reported inactive p300 mutation in B cell lymphoma patients and demonstrated re-activating p300 is toxic to lymphoma cells. CrossRefPubMedPubMedCentralGoogle Scholar
- 34.•• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–95 This manuscript reported for the first time inactivating mutation of CREBBP in DLBCL and follicular lymphoma patients and confirmed the presence of EP300 mutations in DLBCL. It also demonstrated mutant CBP is unable to acetylate p53. CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Mantelingu K, Kishore AH, Balasubramanyam K, et al. Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy. The journal of physical chemistry. B. 2007;111:4527–34.Google Scholar
- 46.Liu Y, Fiorito J, Gonzalez Y, et al. Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma. Blood. 2018;132:37.Google Scholar
- 70.San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.CrossRefPubMedGoogle Scholar
- 73.• Qu K, Zaba LC, Satpathy AT, et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell. 2017;32:27–41 e24 The manuscript demonstrated clinical response to HDAC inhibitors is strongly associated with chromatin accessibility by ATAC-seq. CrossRefPubMedPubMedCentralGoogle Scholar
- 84.Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018;37:1830–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 103.Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.CrossRefPubMedGoogle Scholar
- 117.• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–5 This article reported for the first time the recurrent mutation in EZH2 in large cohorts of DLBCL and follicular lymphoma patients. CrossRefPubMedPubMedCentralGoogle Scholar
- 118.• Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190–8 This manuscript demonstrated the functional consequences of tumor suppressor KMT2D mutations to lymphomagenesis. CrossRefPubMedPubMedCentralGoogle Scholar